BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 38703566)

  • 1. Chemokine‑ and chemokine receptor-based subtypes predict prognosis, immunotherapy and chemotherapy response in colorectal cancer patients.
    Zhu W; Zhao S; Cheng X; Wu C; Liu Z; Huang J
    Int Immunopharmacol; 2024 Jun; 134():112172. PubMed ID: 38703566
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Chemokine- and chemokine receptor-based signature predicts immunotherapy response in female colorectal adenocarcinoma patients.
    Zhu W; Wu C; Hu S; Liu S; Zhao S; Zhang D; Qiu G; Cheng X; Huang J
    Sci Rep; 2023 Dec; 13(1):21358. PubMed ID: 38049474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Computational identification and clinical validation of a novel risk signature based on coagulation-related lncRNAs for predicting prognosis, immunotherapy response, and chemosensitivity in colorectal cancer patients.
    Zhang F; Zhang R; Zong J; Hou Y; Zhou M; Yan Z; Li T; Gan W; Lv S; Yang L; Zeng Z; Zhao W; Yang M
    Front Immunol; 2023; 14():1279789. PubMed ID: 37928532
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comprehensive analysis of a chemokine- and chemokine receptor family-based signature for patients with lung adenocarcinoma.
    Fan T; Liu Y; Liu H; Wang L; Tian H; Zheng Y; Zheng B; Xue L; Tan F; Xue Q; Gao S; Li C; He J
    Cancer Immunol Immunother; 2021 Dec; 70(12):3651-3667. PubMed ID: 33977344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An immune landscape based prognostic signature predicts the immune status and immunotherapeutic responses of patients with colorectal cancer.
    Li M; Li W; Yang X; Wang H; Peng Y; Yin J; Lu Y; Liu L; Shang J; Zhao Q
    Life Sci; 2020 Nov; 261():118368. PubMed ID: 32888940
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A mitophagy-related gene signature associated with prognosis and immune microenvironment in colorectal cancer.
    Zhang C; Zeng C; Xiong S; Zhao Z; Wu G
    Sci Rep; 2022 Nov; 12(1):18688. PubMed ID: 36333388
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel hypoxia- and lactate metabolism-related molecular subtyping and prognostic signature for colorectal cancer.
    Huang A; Sun Z; Hong H; Yang Y; Chen J; Gao Z; Gu J
    J Transl Med; 2024 Jun; 22(1):587. PubMed ID: 38902737
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Identification and validation of an immune prognostic signature in colorectal cancer.
    Li M; Wang H; Li W; Peng Y; Xu F; Shang J; Dong S; Bu L; Wang H; Wei W; Hu Q; Liu L; Zhao Q
    Int Immunopharmacol; 2020 Nov; 88():106868. PubMed ID: 32771948
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive analysis of the relationship between ubiquitin-specific protease 21 (USP21) and prognosis, tumor microenvironment infiltration, and therapy response in colorectal cancer.
    Nie H; Yu Y; Wang F; Huang X; Wang H; Wang J; Tao M; Ning Y; Zhou J; Zhao Q; Xu F; Fang J
    Cancer Immunol Immunother; 2024 Jun; 73(8):156. PubMed ID: 38834869
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Development of an anoikis-related gene signature and prognostic model for predicting the tumor microenvironment and response to immunotherapy in colorectal cancer.
    Li C; Weng J; Yang L; Gong H; Liu Z
    Front Immunol; 2024; 15():1378305. PubMed ID: 38779664
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Transcriptomic correlates of cell cycle checkpoints with distinct prognosis, molecular characteristics, immunological regulation, and therapeutic response in colorectal adenocarcinoma.
    Wang H; Wang W; Wang Z; Li X
    Front Immunol; 2023; 14():1291859. PubMed ID: 38143740
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.
    Liu W; Luo X; Zhang Z; Chen Y; Dai Y; Deng J; Yang C; Liu H
    Cancer Immunol Immunother; 2024 Mar; 73(4):69. PubMed ID: 38430268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical assessment and identification of immuno-oncology markers concerning the 19-gene based risk classifier in stage IV colorectal cancer.
    Lee JL; Roh SA; Kim CW; Kwon YH; Ha YJ; Kim SK; Kim SY; Cho DH; Kim YS; Kim JC
    World J Gastroenterol; 2019 Mar; 25(11):1341-1354. PubMed ID: 30918427
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Development of a novel hypoxia-immune-related LncRNA risk signature for predicting the prognosis and immunotherapy response of colorectal cancer.
    Luan L; Dai Y; Shen T; Yang C; Chen Z; Liu S; Jia J; Li Z; Fang S; Qiu H; Cheng X; Yang Z
    Front Immunol; 2022; 13():951455. PubMed ID: 36189298
    [TBL] [Abstract][Full Text] [Related]  

  • 15. N6-Methyladenosine-Related lncRNA Signature Predicts the Overall Survival of Colorectal Cancer Patients.
    Song W; Ren J; Yuan W; Xiang R; Ge Y; Fu T
    Genes (Basel); 2021 Aug; 12(9):. PubMed ID: 34573357
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stratified analysis reveals chemokine-like factor (CKLF) as a potential prognostic marker in the MSI-immune consensus molecular subtype CMS1 of colorectal cancer.
    Dunne PD; O'Reilly PG; Coleman HG; Gray RT; Longley DB; Johnston PG; Salto-Tellez M; Lawler M; McArt DG
    Oncotarget; 2016 Jun; 7(24):36632-36644. PubMed ID: 27153559
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comprehensive Analysis of a Cancer-Immunity Cycle-Based Signature for Predicting Prognosis and Immunotherapy Response in Patients With Colorectal Cancer.
    Hou Y; Zhang R; Zong J; Wang W; Zhou M; Yan Z; Li T; Gan W; Lv S; Zeng Z; Yang M
    Front Immunol; 2022; 13():892512. PubMed ID: 35711437
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development and Validation of a TNF Family-Based Signature for Predicting Prognosis, Tumor Immune Characteristics, and Immunotherapy Response in Colorectal Cancer Patients.
    Xiao Z; Nie K; Han T; Cheng L; Zhang Z; Peng W; Shi D
    J Immunol Res; 2021; 2021():6439975. PubMed ID: 34541005
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor microenvironment-related gene selenium-binding protein 1 (SELENBP1) is associated with immunotherapy efficacy and survival in colorectal cancer.
    Zhu C; Wang S; Du Y; Dai Y; Huai Q; Li X; Du Y; Dai H; Yuan W; Yin S; Wang H
    BMC Gastroenterol; 2022 Oct; 22(1):437. PubMed ID: 36253721
    [TBL] [Abstract][Full Text] [Related]  

  • 20. An inflammation-related subtype classification for analyzing tumor microenvironment and clinical prognosis in colorectal cancer.
    Pei J; Gao Y; Wu A
    Front Immunol; 2024; 15():1369726. PubMed ID: 38742117
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.